Some hospitals are finding it difficult to scale AI across their enterprise — with this process often complicated by things like inadequate technology infrastructures, varying needs across ...

The Trump administration is not finalizing a Biden-era provision that would expand coverage of anti-obesity drugs under ...

Immunology continues to be one of the most active areas for drug research as the field aims to bring patients new ways to eliminate the antibodies driving autoimmune disease, but in a manner that ...

It is well documented that access to primary care in the U.S. is decreasing. The cause is multi-factorial. Some of the problems are a result of patient-related factors, such as mobility and ...

AI is the theme of the clinical-facing health tech track in the INVEST Pitch Perfect contest, scheduled to take place at the Willis Tower in Chicago from May 20-21. Among the investor judges for ...

The Senate confirmed Dr. Mehmet Oz, a celebrity TV doctor, as CMS administrator last week on a 53-45 vote, which was along party lines. In the position, Oz will lead the Medicare and Medicaid ...

Before GLP-1 agonists became the blockbuster obesity drugs many people know and use today, Rhythm Pharmaceuticals was researching molecules that take a similar approach but for a different target.

Benefits leaders at the nation’s largest employers are managing massive healthcare cost increases, and that’s driving change in how they design their health benefits offerings. I’ve talked ...

The Supreme Court will soon hear oral arguments for a case that threatens coverage of preventive services without ...

The AI change management process that healthcare providers are navigating will be as significant — if not more so — than the industry’s transition to EHRs, according to Michael Meucci, CEO ...